Tsukamoto Hironobu, Mizoshita Tsutomu, Katano Takahito, Hayashi Noriyuki, Ozeki Keiji, Ebi Masahide, Shimura Takaya, Mori Yoshinori, Tanida Satoshi, Kataoka Hiromi, Tsukamoto Tetsuya, Tatematsu Masae, Joh Takashi
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Exp Toxicol Pathol. 2015 Mar;67(3):271-7. doi: 10.1016/j.etp.2015.01.003. Epub 2015 Jan 20.
Chemoprevention strategies against gastric cancer (GC) need to be explored in light of the fact that stomach cancer still occurs in the absence of Helicobacter pylori (HP) infection and following HP eradication. We evaluated the effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced carcinogenesis in SD rats. Thirty-nine male rats were divided into four groups based on whether or not they were treated with rebamipide and/or MNNG: Control, Rebamipide, Control-M, and Rebamipide-M groups. From 8 weeks of age, rats in the Control-M and Rebamipide-M groups received MNNG in drinking water for 30 weeks. The Rebamipide and Rebamipide-M groups were administered 5mg/kg/day of rebamipide. At 50 weeks, cancerous lesions were not observed in either the Control or Rebamipide groups. Nine rats in the Control-M group had developed GC, while four rats in the Rebamipide-M group had developed GC. The incidence of cancer in the Rebamipide-M group was significantly less than in the Control-M group (p<0.05), with a trend toward a lower incidence of invasive carcinoma in the Rebamipide-M group. Carcinomatous invasion into the muscularis propria was not observed in the Rebamipide-M group. In conclusion, the present study demonstrates that rebamipide suppresses. MNNG-induced carcinogenesis and may also inhibit progression of cancer in rats.
鉴于在没有幽门螺杆菌（HP）感染以及根除HP之后仍会发生胃癌，因此需要探索针对胃癌（GC）的化学预防策略。我们评估了瑞巴派特对N-甲基-N'-硝基-N-亚硝基胍（MNNG）诱导的SD大鼠致癌作用的影响。39只雄性大鼠根据是否接受瑞巴派特和/或MNNG治疗分为四组：对照组、瑞巴派特组、对照-M组和瑞巴派特-M组。从8周龄开始，对照-M组和瑞巴派特-M组的大鼠在饮用水中接受MNNG处理30周。瑞巴派特组和瑞巴派特-M组给予5mg/kg/天的瑞巴派特。在50周时，对照组和瑞巴派特组均未观察到癌性病变。对照-M组有9只大鼠发生了GC，而瑞巴派特-M组有4只大鼠发生了GC。瑞巴派特-M组的癌症发生率明显低于对照-M组（p<0.05），瑞巴派特-M组浸润性癌的发生率有降低趋势。瑞巴派特-M组未观察到癌组织侵犯固有肌层。总之，本研究表明瑞巴派特可抑制MNNG诱导的致癌作用，并且可能还会抑制大鼠癌症的进展。
